AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Matinas BioPharma Announces Stock Sale for Shareholders
ByAinvest
Thursday, Apr 24, 2025 8:54 pm ET1min read
Matinas BioPharma has filed to sell 16.9 million shares of common stock for holders. The move is aimed at raising capital to support the company's operations and growth. The filing does not specify the exact amount of money the company plans to raise. As a finance expert, I would note that the sale of common stock is a common practice for biotech companies looking to raise capital and fund their research and development efforts.
Matinas BioPharma Holdings, Inc. has filed with the Securities and Exchange Commission (SEC) to sell up to 16,894,212 shares of common stock. The move is aimed at raising capital to support the company's operations and growth, as disclosed in a Form S-3 registration statement filed on April 22, 2025 [1]. The exact amount of money the company plans to raise is not specified in the filing.The sale of common stock is a common practice for biotech companies looking to raise capital and fund their research and development efforts. This latest filing by Matinas BioPharma is a strategic move to secure additional funding, which could potentially accelerate the company's growth and innovation in the biopharmaceutical sector.
The shares of common stock are being offered by the Selling Stockholders, who include holders of Series C Convertible Preferred Stock and warrants issued in a private placement offering. The private placement closed in two separate closings on February 13, 2025, and April 8, 2025 [1].
Investors should be aware that the sale of these securities involves a high degree of risk, as outlined in the company's annual report and other filings with the SEC [1]. The SEC has not approved or disapproved of these securities, and the preliminary prospectus is subject to completion and may be changed [1].
Matinas BioPharma's common stock is listed on the NYSE American under the symbol "MTNB." The last reported sale price of the common stock as of April 21, 2025, was $0.5570 [1].
References:
[1] https://quantisnow.com/insight/sec-form-s3-filed-by-matinas-biopharma-holdings-inc-5996867
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet